Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies. Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete. Have a look at our website for further information and follow us on LinkedIn for fresh updates on our journey. There is a lot to come! Imprint: https://www.lumatix.bio/imprint-data-protection/ The start-up project Lumatix Biotech is funded by the Federal Ministry for Economic Affairs and Energy funding program “EXIST Transfer of Research” and is co-financed by the European Social Fund.